nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisinopril—Nateglinide—Bortezomib—hematologic cancer	0.196	0.513	CrCrCtD
Lisinopril—Aspartame—Bortezomib—hematologic cancer	0.186	0.487	CrCrCtD
Lisinopril—ABCB1—hematologic cancer	0.117	1	CbGaD
Lisinopril—ABCB1—Lenalidomide—hematologic cancer	0.0283	0.141	CbGbCtD
Lisinopril—ABCB1—Daunorubicin—hematologic cancer	0.0166	0.0826	CbGbCtD
Lisinopril—ABCB1—Alitretinoin—hematologic cancer	0.0163	0.0809	CbGbCtD
Lisinopril—ABCB1—Imatinib—hematologic cancer	0.0127	0.0633	CbGbCtD
Lisinopril—ABCB1—Nilotinib—hematologic cancer	0.0116	0.0575	CbGbCtD
Lisinopril—ABCB1—Vinorelbine—hematologic cancer	0.0115	0.057	CbGbCtD
Lisinopril—ABCB1—Dasatinib—hematologic cancer	0.0102	0.0508	CbGbCtD
Lisinopril—ABCB1—Mitoxantrone—hematologic cancer	0.0101	0.0502	CbGbCtD
Lisinopril—ABCB1—Betamethasone—hematologic cancer	0.00899	0.0447	CbGbCtD
Lisinopril—ABCB1—Gemcitabine—hematologic cancer	0.00891	0.0443	CbGbCtD
Lisinopril—ABCB1—Prednisolone—hematologic cancer	0.00887	0.0442	CbGbCtD
Lisinopril—ABCB1—Prednisone—hematologic cancer	0.00837	0.0417	CbGbCtD
Lisinopril—ABCB1—Irinotecan—hematologic cancer	0.00794	0.0395	CbGbCtD
Lisinopril—ABCB1—Vinblastine—hematologic cancer	0.00706	0.0351	CbGbCtD
Lisinopril—ABCB1—Vincristine—hematologic cancer	0.00694	0.0345	CbGbCtD
Lisinopril—ABCB1—Cisplatin—hematologic cancer	0.00647	0.0322	CbGbCtD
Lisinopril—ABCB1—Etoposide—hematologic cancer	0.00636	0.0317	CbGbCtD
Lisinopril—ABCB1—Dexamethasone—hematologic cancer	0.00523	0.026	CbGbCtD
Lisinopril—ABCB1—Doxorubicin—hematologic cancer	0.00434	0.0216	CbGbCtD
Lisinopril—ABCB1—Methotrexate—hematologic cancer	0.0042	0.0209	CbGbCtD
Lisinopril—ACE2—hematopoietic system—hematologic cancer	0.004	0.167	CbGeAlD
Lisinopril—ACE2—gonad—hematologic cancer	0.00304	0.127	CbGeAlD
Lisinopril—ACE2—blood—hematologic cancer	0.00265	0.111	CbGeAlD
Lisinopril—ACE2—lung—hematologic cancer	0.00232	0.0972	CbGeAlD
Lisinopril—ACE2—testis—hematologic cancer	0.00219	0.0917	CbGeAlD
Lisinopril—ACE2—lymph node—hematologic cancer	0.00159	0.0665	CbGeAlD
Lisinopril—ACE—hematopoietic system—hematologic cancer	0.00131	0.0547	CbGeAlD
Lisinopril—ACE—gonad—hematologic cancer	0.000993	0.0416	CbGeAlD
Lisinopril—ACE—blood—hematologic cancer	0.000865	0.0362	CbGeAlD
Lisinopril—ACE—bone marrow—hematologic cancer	0.000837	0.0351	CbGeAlD
Lisinopril—ACE—lung—hematologic cancer	0.000759	0.0318	CbGeAlD
Lisinopril—ACE—testis—hematologic cancer	0.000716	0.03	CbGeAlD
Lisinopril—ACE—lymph node—hematologic cancer	0.000519	0.0217	CbGeAlD
Lisinopril—ABCB1—hematopoietic system—hematologic cancer	0.00046	0.0193	CbGeAlD
Lisinopril—ABCB1—gonad—hematologic cancer	0.00035	0.0146	CbGeAlD
Lisinopril—ABCB1—blood—hematologic cancer	0.000305	0.0128	CbGeAlD
Lisinopril—ABCB1—bone marrow—hematologic cancer	0.000295	0.0123	CbGeAlD
Lisinopril—ABCB1—lung—hematologic cancer	0.000267	0.0112	CbGeAlD
Lisinopril—ABCB1—testis—hematologic cancer	0.000252	0.0106	CbGeAlD
Lisinopril—ABCB1—lymph node—hematologic cancer	0.000183	0.00765	CbGeAlD
Lisinopril—Benazepril—MTHFR—hematologic cancer	0.000175	0.547	CrCbGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—BNIP3—hematologic cancer	0.000171	0.00262	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—SPHK1—hematologic cancer	0.00017	0.00259	CbGpPWpGaD
Lisinopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—hematologic cancer	0.000167	0.00256	CbGpPWpGaD
Lisinopril—ABCB1—Constitutive Androstane Receptor Pathway—UGT1A1—hematologic cancer	0.000165	0.00252	CbGpPWpGaD
Lisinopril—ABCB1—ABC-family proteins mediated transport—ABCC3—hematologic cancer	0.00016	0.00244	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—CTSZ—hematologic cancer	0.000158	0.00242	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—ANPEP—hematologic cancer	0.000158	0.00242	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—GATA2—hematologic cancer	0.000158	0.00242	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—RPS14—hematologic cancer	0.000152	0.00232	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000151	0.0023	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—DPM1—hematologic cancer	0.000149	0.00228	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—ASNS—hematologic cancer	0.000149	0.00228	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CSF1R—hematologic cancer	0.000147	0.00224	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—ID2—hematologic cancer	0.000136	0.00208	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—PREB—hematologic cancer	0.000135	0.00206	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000134	0.00205	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—PPP1R13L—hematologic cancer	0.000133	0.00204	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—EIF4EBP1—hematologic cancer	0.000133	0.00203	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—GCNT1—hematologic cancer	0.000129	0.00198	CbGpPWpGaD
Lisinopril—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—hematologic cancer	0.000129	0.00197	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—HSPA5—hematologic cancer	0.000123	0.00188	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—CALR—hematologic cancer	0.000119	0.00182	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—MCL1—hematologic cancer	0.000116	0.00177	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—FBXW7—hematologic cancer	0.000115	0.00176	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CCND3—hematologic cancer	0.000113	0.00173	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—MUC1—hematologic cancer	0.00011	0.00168	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000109	0.00166	CbGpPWpGaD
Lisinopril—ABCB1—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	0.000106	0.00163	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—CA9—hematologic cancer	0.000106	0.00162	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CXCR5—hematologic cancer	0.000104	0.00159	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABCG2—hematologic cancer	0.000102	0.00156	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000101	0.00155	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—RPLP1—hematologic cancer	9.6e-05	0.00147	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CXCL13—hematologic cancer	9.15e-05	0.0014	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—NPM1—hematologic cancer	9.07e-05	0.00139	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	8.88e-05	0.00136	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—TUBB2A—hematologic cancer	8.81e-05	0.00135	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—hematologic cancer	8.72e-05	0.00133	CbGpPWpGaD
Lisinopril—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	8.44e-05	0.00129	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—hematologic cancer	8.42e-05	0.00129	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—NUP98—hematologic cancer	8.38e-05	0.00128	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—S100A10—hematologic cancer	8.23e-05	0.00126	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—NUP214—hematologic cancer	8.08e-05	0.00124	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—ABCG2—hematologic cancer	8.01e-05	0.00123	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—FOXP3—hematologic cancer	7.85e-05	0.0012	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—MME—hematologic cancer	7.83e-05	0.0012	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—CMA1—hematologic cancer	7.74e-05	0.00118	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—SUMO1—hematologic cancer	7.74e-05	0.00118	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	7.65e-05	0.00117	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—SPHK1—hematologic cancer	7.57e-05	0.00116	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	7.2e-05	0.0011	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—TFRC—hematologic cancer	7.14e-05	0.00109	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—EPO—hematologic cancer	6.87e-05	0.00105	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	6.82e-05	0.00104	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—RPS14—hematologic cancer	6.79e-05	0.00104	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—GZMB—hematologic cancer	6.72e-05	0.00103	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—IL13—hematologic cancer	6.72e-05	0.00103	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—hematologic cancer	6.55e-05	0.001	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—CXCR4—hematologic cancer	6.4e-05	0.00098	CbGpPWpGaD
Lisinopril—Cilazapril—ABCB1—hematologic cancer	6.4e-05	0.2	CrCbGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ATP4A—hematologic cancer	6.24e-05	0.000955	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SGK1—hematologic cancer	6.24e-05	0.000955	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ANXA2—hematologic cancer	6.24e-05	0.000955	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CASP7—hematologic cancer	6.15e-05	0.000942	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—hematologic cancer	5.99e-05	0.000917	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—hematologic cancer	5.96e-05	0.000912	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—PRKCZ—hematologic cancer	5.95e-05	0.000911	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—EIF4EBP1—hematologic cancer	5.93e-05	0.000908	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—CCL2—hematologic cancer	5.92e-05	0.000906	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—hematologic cancer	5.9e-05	0.000903	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	5.62e-05	0.00086	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—HSPA5—hematologic cancer	5.49e-05	0.00084	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CD40—hematologic cancer	5.48e-05	0.000839	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—CALR—hematologic cancer	5.32e-05	0.000814	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—hematologic cancer	5.31e-05	0.000813	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—FBXW7—hematologic cancer	5.14e-05	0.000787	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—STAT1—hematologic cancer	4.97e-05	0.000761	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	4.93e-05	0.000755	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—HLA-DQA1—hematologic cancer	4.76e-05	0.000728	CbGpPWpGaD
Lisinopril—Enalapril—ABCB1—hematologic cancer	4.7e-05	0.147	CrCbGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—hematologic cancer	4.57e-05	0.0007	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	4.51e-05	0.00069	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—hematologic cancer	4.4e-05	0.000674	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CD86—hematologic cancer	4.29e-05	0.000656	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—TERT—hematologic cancer	4.28e-05	0.000655	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—NUP98—hematologic cancer	4.26e-05	0.000652	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—IL10—hematologic cancer	4.2e-05	0.000643	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CD40LG—hematologic cancer	4.2e-05	0.000643	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	4.13e-05	0.000632	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—NUP214—hematologic cancer	4.1e-05	0.000628	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—IL4—hematologic cancer	4.09e-05	0.000626	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—PDGFRA—hematologic cancer	4.03e-05	0.000616	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	4.02e-05	0.000615	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—HLA-B—hematologic cancer	4e-05	0.000612	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—hematologic cancer	3.95e-05	0.000604	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—FASLG—hematologic cancer	3.91e-05	0.000598	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—FAS—hematologic cancer	3.77e-05	0.000577	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—IL2RA—hematologic cancer	3.75e-05	0.000573	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—hematologic cancer	3.74e-05	0.000573	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—HLA-A—hematologic cancer	3.7e-05	0.000567	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—AQP9—hematologic cancer	3.67e-05	0.000562	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—TFRC—hematologic cancer	3.58e-05	0.000548	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—hematologic cancer	3.54e-05	0.000542	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—FOS—hematologic cancer	3.44e-05	0.000526	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—CREB1—hematologic cancer	3.43e-05	0.000525	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—FXYD6—hematologic cancer	3.41e-05	0.000523	CbGpPWpGaD
Lisinopril—Nateglinide—ALB—hematologic cancer	3.36e-05	0.105	CrCbGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—CREBBP—hematologic cancer	3.34e-05	0.000511	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—PML—hematologic cancer	3.34e-05	0.000511	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—hematologic cancer	3.29e-05	0.000503	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CD80—hematologic cancer	3.13e-05	0.000478	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—ALB—hematologic cancer	3.09e-05	0.000473	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—TOP2A—hematologic cancer	3.05e-05	0.000467	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CASP7—hematologic cancer	3.04e-05	0.000465	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—CYCS—hematologic cancer	3.01e-05	0.00046	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CASP8—hematologic cancer	2.91e-05	0.000445	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—hematologic cancer	2.9e-05	0.000443	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—S100A10—hematologic cancer	2.78e-05	0.000426	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—CCL2—hematologic cancer	2.64e-05	0.000404	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—hematologic cancer	2.64e-05	0.000404	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	2.59e-05	0.000396	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—hematologic cancer	2.52e-05	0.000385	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ABCB1—hematologic cancer	2.51e-05	0.000384	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—IFNG—hematologic cancer	2.47e-05	0.000378	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—JUN—hematologic cancer	2.47e-05	0.000378	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—STAT1—hematologic cancer	2.45e-05	0.000375	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	2.43e-05	0.000372	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—AR—hematologic cancer	2.37e-05	0.000363	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	2.31e-05	0.000353	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—GRB2—hematologic cancer	2.3e-05	0.000351	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFA—hematologic cancer	2.29e-05	0.00035	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—EP300—hematologic cancer	2.28e-05	0.000348	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—STAT5A—hematologic cancer	2.21e-05	0.000338	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—hematologic cancer	2.21e-05	0.000338	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—IL1B—hematologic cancer	2.2e-05	0.000337	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CASP3—hematologic cancer	2.2e-05	0.000337	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—IL2—hematologic cancer	2.2e-05	0.000336	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—hematologic cancer	2.19e-05	0.000335	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—VEGFA—hematologic cancer	2.16e-05	0.00033	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ATP4A—hematologic cancer	2.11e-05	0.000323	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ANXA2—hematologic cancer	2.11e-05	0.000323	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SGK1—hematologic cancer	2.11e-05	0.000323	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—FGF1—hematologic cancer	2.05e-05	0.000314	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—hematologic cancer	2.02e-05	0.000309	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—hematologic cancer	1.99e-05	0.000304	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—hematologic cancer	1.93e-05	0.000295	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	1.9e-05	0.000291	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GMPS—hematologic cancer	1.88e-05	0.000288	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PHYH—hematologic cancer	1.88e-05	0.000288	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—FTCD—hematologic cancer	1.88e-05	0.000288	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—VEGFA—hematologic cancer	1.87e-05	0.000286	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—hematologic cancer	1.86e-05	0.000285	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—hematologic cancer	1.73e-05	0.000265	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—SMPD3—hematologic cancer	1.72e-05	0.000263	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—TGFB1—hematologic cancer	1.71e-05	0.000262	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.68e-05	0.000257	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	1.67e-05	0.000255	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—hematologic cancer	1.66e-05	0.000254	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—hematologic cancer	1.64e-05	0.000251	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—hematologic cancer	1.64e-05	0.00025	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—hematologic cancer	1.63e-05	0.000249	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—TNF—hematologic cancer	1.6e-05	0.000245	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—hematologic cancer	1.59e-05	0.000243	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—hematologic cancer	1.59e-05	0.000243	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.57e-05	0.00024	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	1.53e-05	0.000233	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—B3GAT1—hematologic cancer	1.5e-05	0.00023	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—DCK—hematologic cancer	1.5e-05	0.00023	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ASNS—hematologic cancer	1.5e-05	0.00023	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—hematologic cancer	1.47e-05	0.000224	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—NUP98—hematologic cancer	1.44e-05	0.00022	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—hematologic cancer	1.43e-05	0.00022	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—hematologic cancer	1.43e-05	0.000219	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—HDC—hematologic cancer	1.43e-05	0.000218	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	1.4e-05	0.000214	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—NUP214—hematologic cancer	1.39e-05	0.000212	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—AKT1—hematologic cancer	1.38e-05	0.00021	CbGpPWpGaD
Lisinopril—Dermatitis—Cisplatin—hematologic cancer	1.37e-05	6.51e-05	CcSEcCtD
Lisinopril—Erythema—Epirubicin—hematologic cancer	1.37e-05	6.51e-05	CcSEcCtD
Lisinopril—Malnutrition—Epirubicin—hematologic cancer	1.37e-05	6.51e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—hematologic cancer	1.36e-05	0.000209	CbGpPWpGaD
Lisinopril—Diarrhoea—Etoposide—hematologic cancer	1.36e-05	6.48e-05	CcSEcCtD
Lisinopril—Anorexia—Prednisone—hematologic cancer	1.36e-05	6.47e-05	CcSEcCtD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	1.36e-05	0.000208	CbGpPWpGaD
Lisinopril—Ill-defined disorder—Methotrexate—hematologic cancer	1.36e-05	6.45e-05	CcSEcCtD
Lisinopril—Tinnitus—Doxorubicin—hematologic cancer	1.36e-05	6.45e-05	CcSEcCtD
Lisinopril—Anaemia—Methotrexate—hematologic cancer	1.35e-05	6.43e-05	CcSEcCtD
Lisinopril—Feeling abnormal—Dexamethasone—hematologic cancer	1.35e-05	6.42e-05	CcSEcCtD
Lisinopril—Feeling abnormal—Betamethasone—hematologic cancer	1.35e-05	6.42e-05	CcSEcCtD
Lisinopril—Flushing—Doxorubicin—hematologic cancer	1.35e-05	6.42e-05	CcSEcCtD
Lisinopril—Flatulence—Epirubicin—hematologic cancer	1.35e-05	6.41e-05	CcSEcCtD
Lisinopril—Tension—Epirubicin—hematologic cancer	1.34e-05	6.39e-05	CcSEcCtD
Lisinopril—Gastrointestinal pain—Betamethasone—hematologic cancer	1.34e-05	6.38e-05	CcSEcCtD
Lisinopril—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.34e-05	6.38e-05	CcSEcCtD
Lisinopril—Dysgeusia—Epirubicin—hematologic cancer	1.34e-05	6.37e-05	CcSEcCtD
Lisinopril—Hypersensitivity—Triamcinolone—hematologic cancer	1.33e-05	6.33e-05	CcSEcCtD
Lisinopril—Nervousness—Epirubicin—hematologic cancer	1.33e-05	6.32e-05	CcSEcCtD
Lisinopril—Back pain—Epirubicin—hematologic cancer	1.32e-05	6.29e-05	CcSEcCtD
Lisinopril—Angiopathy—Doxorubicin—hematologic cancer	1.32e-05	6.27e-05	CcSEcCtD
Lisinopril—Malaise—Methotrexate—hematologic cancer	1.32e-05	6.27e-05	CcSEcCtD
Lisinopril—Dizziness—Etoposide—hematologic cancer	1.32e-05	6.26e-05	CcSEcCtD
Lisinopril—Muscle spasms—Epirubicin—hematologic cancer	1.31e-05	6.26e-05	CcSEcCtD
Lisinopril—Vertigo—Methotrexate—hematologic cancer	1.31e-05	6.25e-05	CcSEcCtD
Lisinopril—Mediastinal disorder—Doxorubicin—hematologic cancer	1.31e-05	6.23e-05	CcSEcCtD
Lisinopril—Leukopenia—Methotrexate—hematologic cancer	1.31e-05	6.22e-05	CcSEcCtD
Lisinopril—Chills—Doxorubicin—hematologic cancer	1.3e-05	6.21e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—CDA—hematologic cancer	1.3e-05	0.0002	CbGpPWpGaD
Lisinopril—Urticaria—Dexamethasone—hematologic cancer	1.3e-05	6.19e-05	CcSEcCtD
Lisinopril—Urticaria—Betamethasone—hematologic cancer	1.3e-05	6.19e-05	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.3e-05	6.19e-05	CcSEcCtD
Lisinopril—Dizziness—Prednisolone—hematologic cancer	1.3e-05	6.18e-05	CcSEcCtD
Lisinopril—Arrhythmia—Doxorubicin—hematologic cancer	1.3e-05	6.18e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—hematologic cancer	1.3e-05	0.000198	CbGpPWpGaD
Lisinopril—Asthenia—Triamcinolone—hematologic cancer	1.3e-05	6.17e-05	CcSEcCtD
Lisinopril—Body temperature increased—Betamethasone—hematologic cancer	1.3e-05	6.16e-05	CcSEcCtD
Lisinopril—Abdominal pain—Dexamethasone—hematologic cancer	1.3e-05	6.16e-05	CcSEcCtD
Lisinopril—Abdominal pain—Betamethasone—hematologic cancer	1.3e-05	6.16e-05	CcSEcCtD
Lisinopril—Body temperature increased—Dexamethasone—hematologic cancer	1.3e-05	6.16e-05	CcSEcCtD
Lisinopril—Nausea—Cisplatin—hematologic cancer	1.29e-05	6.14e-05	CcSEcCtD
Lisinopril—Insomnia—Prednisone—hematologic cancer	1.29e-05	6.14e-05	CcSEcCtD
Lisinopril—Vision blurred—Epirubicin—hematologic cancer	1.29e-05	6.13e-05	CcSEcCtD
Lisinopril—Alopecia—Doxorubicin—hematologic cancer	1.28e-05	6.11e-05	CcSEcCtD
Lisinopril—Paraesthesia—Prednisone—hematologic cancer	1.28e-05	6.1e-05	CcSEcCtD
Lisinopril—Pruritus—Triamcinolone—hematologic cancer	1.28e-05	6.08e-05	CcSEcCtD
Lisinopril—Cough—Methotrexate—hematologic cancer	1.28e-05	6.07e-05	CcSEcCtD
Lisinopril—Mental disorder—Doxorubicin—hematologic cancer	1.27e-05	6.06e-05	CcSEcCtD
Lisinopril—Ill-defined disorder—Epirubicin—hematologic cancer	1.27e-05	6.04e-05	CcSEcCtD
Lisinopril—Vomiting—Etoposide—hematologic cancer	1.27e-05	6.02e-05	CcSEcCtD
Lisinopril—Malnutrition—Doxorubicin—hematologic cancer	1.27e-05	6.02e-05	CcSEcCtD
Lisinopril—Erythema—Doxorubicin—hematologic cancer	1.27e-05	6.02e-05	CcSEcCtD
Lisinopril—Anaemia—Epirubicin—hematologic cancer	1.26e-05	6.01e-05	CcSEcCtD
Lisinopril—Dyspepsia—Prednisone—hematologic cancer	1.26e-05	5.98e-05	CcSEcCtD
Lisinopril—Rash—Etoposide—hematologic cancer	1.26e-05	5.97e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—PC—hematologic cancer	1.25e-05	0.000192	CbGpPWpGaD
Lisinopril—Dermatitis—Etoposide—hematologic cancer	1.25e-05	5.97e-05	CcSEcCtD
Lisinopril—Headache—Etoposide—hematologic cancer	1.25e-05	5.93e-05	CcSEcCtD
Lisinopril—Flatulence—Doxorubicin—hematologic cancer	1.25e-05	5.93e-05	CcSEcCtD
Lisinopril—Chest pain—Methotrexate—hematologic cancer	1.24e-05	5.92e-05	CcSEcCtD
Lisinopril—Myalgia—Methotrexate—hematologic cancer	1.24e-05	5.92e-05	CcSEcCtD
Lisinopril—Arthralgia—Methotrexate—hematologic cancer	1.24e-05	5.92e-05	CcSEcCtD
Lisinopril—Tension—Doxorubicin—hematologic cancer	1.24e-05	5.91e-05	CcSEcCtD
Lisinopril—Decreased appetite—Prednisone—hematologic cancer	1.24e-05	5.9e-05	CcSEcCtD
Lisinopril—Dysgeusia—Doxorubicin—hematologic cancer	1.24e-05	5.9e-05	CcSEcCtD
Lisinopril—Rash—Prednisolone—hematologic cancer	1.24e-05	5.89e-05	CcSEcCtD
Lisinopril—Dermatitis—Prednisolone—hematologic cancer	1.24e-05	5.89e-05	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.24e-05	5.88e-05	CcSEcCtD
Lisinopril—Malaise—Epirubicin—hematologic cancer	1.23e-05	5.87e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—hematologic cancer	1.23e-05	0.000188	CbGpPWpGaD
Lisinopril—Fatigue—Prednisone—hematologic cancer	1.23e-05	5.85e-05	CcSEcCtD
Lisinopril—Headache—Prednisolone—hematologic cancer	1.23e-05	5.85e-05	CcSEcCtD
Lisinopril—Discomfort—Methotrexate—hematologic cancer	1.23e-05	5.85e-05	CcSEcCtD
Lisinopril—Nervousness—Doxorubicin—hematologic cancer	1.23e-05	5.85e-05	CcSEcCtD
Lisinopril—Vertigo—Epirubicin—hematologic cancer	1.23e-05	5.85e-05	CcSEcCtD
Lisinopril—Syncope—Epirubicin—hematologic cancer	1.23e-05	5.84e-05	CcSEcCtD
Lisinopril—Leukopenia—Epirubicin—hematologic cancer	1.22e-05	5.82e-05	CcSEcCtD
Lisinopril—Back pain—Doxorubicin—hematologic cancer	1.22e-05	5.82e-05	CcSEcCtD
Lisinopril—Constipation—Prednisone—hematologic cancer	1.22e-05	5.81e-05	CcSEcCtD
Lisinopril—Muscle spasms—Doxorubicin—hematologic cancer	1.22e-05	5.79e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—hematologic cancer	1.21e-05	0.000186	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GBA—hematologic cancer	1.21e-05	0.000185	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—SLC35B2—hematologic cancer	1.21e-05	0.000185	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—TFRC—hematologic cancer	1.21e-05	0.000185	CbGpPWpGaD
Lisinopril—Palpitations—Epirubicin—hematologic cancer	1.21e-05	5.75e-05	CcSEcCtD
Lisinopril—Confusional state—Methotrexate—hematologic cancer	1.2e-05	5.72e-05	CcSEcCtD
Lisinopril—Loss of consciousness—Epirubicin—hematologic cancer	1.2e-05	5.72e-05	CcSEcCtD
Lisinopril—Dizziness—Triamcinolone—hematologic cancer	1.19e-05	5.68e-05	CcSEcCtD
Lisinopril—Cough—Epirubicin—hematologic cancer	1.19e-05	5.68e-05	CcSEcCtD
Lisinopril—Anaphylactic shock—Methotrexate—hematologic cancer	1.19e-05	5.67e-05	CcSEcCtD
Lisinopril—Vision blurred—Doxorubicin—hematologic cancer	1.19e-05	5.67e-05	CcSEcCtD
Lisinopril—Infection—Methotrexate—hematologic cancer	1.18e-05	5.64e-05	CcSEcCtD
Lisinopril—Nausea—Etoposide—hematologic cancer	1.18e-05	5.63e-05	CcSEcCtD
Lisinopril—Feeling abnormal—Prednisone—hematologic cancer	1.18e-05	5.6e-05	CcSEcCtD
Lisinopril—Asthenia—Betamethasone—hematologic cancer	1.18e-05	5.59e-05	CcSEcCtD
Lisinopril—Asthenia—Dexamethasone—hematologic cancer	1.18e-05	5.59e-05	CcSEcCtD
Lisinopril—Ill-defined disorder—Doxorubicin—hematologic cancer	1.17e-05	5.59e-05	CcSEcCtD
Lisinopril—Anaemia—Doxorubicin—hematologic cancer	1.17e-05	5.56e-05	CcSEcCtD
Lisinopril—Thrombocytopenia—Methotrexate—hematologic cancer	1.17e-05	5.56e-05	CcSEcCtD
Lisinopril—Gastrointestinal pain—Prednisone—hematologic cancer	1.17e-05	5.55e-05	CcSEcCtD
Lisinopril—Nausea—Prednisolone—hematologic cancer	1.17e-05	5.55e-05	CcSEcCtD
Lisinopril—Arthralgia—Epirubicin—hematologic cancer	1.16e-05	5.54e-05	CcSEcCtD
Lisinopril—Chest pain—Epirubicin—hematologic cancer	1.16e-05	5.54e-05	CcSEcCtD
Lisinopril—Myalgia—Epirubicin—hematologic cancer	1.16e-05	5.54e-05	CcSEcCtD
Lisinopril—Anxiety—Epirubicin—hematologic cancer	1.16e-05	5.52e-05	CcSEcCtD
Lisinopril—Pruritus—Betamethasone—hematologic cancer	1.16e-05	5.52e-05	CcSEcCtD
Lisinopril—Pruritus—Dexamethasone—hematologic cancer	1.16e-05	5.52e-05	CcSEcCtD
Lisinopril—Skin disorder—Methotrexate—hematologic cancer	1.16e-05	5.51e-05	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.16e-05	5.5e-05	CcSEcCtD
Lisinopril—Hyperhidrosis—Methotrexate—hematologic cancer	1.15e-05	5.49e-05	CcSEcCtD
Lisinopril—Discomfort—Epirubicin—hematologic cancer	1.15e-05	5.47e-05	CcSEcCtD
Lisinopril—Vomiting—Triamcinolone—hematologic cancer	1.15e-05	5.46e-05	CcSEcCtD
Lisinopril—Malaise—Doxorubicin—hematologic cancer	1.14e-05	5.43e-05	CcSEcCtD
Lisinopril—Rash—Triamcinolone—hematologic cancer	1.14e-05	5.42e-05	CcSEcCtD
Lisinopril—Dry mouth—Epirubicin—hematologic cancer	1.14e-05	5.42e-05	CcSEcCtD
Lisinopril—Dermatitis—Triamcinolone—hematologic cancer	1.14e-05	5.41e-05	CcSEcCtD
Lisinopril—Vertigo—Doxorubicin—hematologic cancer	1.14e-05	5.41e-05	CcSEcCtD
Lisinopril—Anorexia—Methotrexate—hematologic cancer	1.14e-05	5.41e-05	CcSEcCtD
Lisinopril—Syncope—Doxorubicin—hematologic cancer	1.13e-05	5.4e-05	CcSEcCtD
Lisinopril—Urticaria—Prednisone—hematologic cancer	1.13e-05	5.39e-05	CcSEcCtD
Lisinopril—Leukopenia—Doxorubicin—hematologic cancer	1.13e-05	5.39e-05	CcSEcCtD
Lisinopril—Headache—Triamcinolone—hematologic cancer	1.13e-05	5.38e-05	CcSEcCtD
Lisinopril—Abdominal pain—Prednisone—hematologic cancer	1.13e-05	5.37e-05	CcSEcCtD
Lisinopril—Body temperature increased—Prednisone—hematologic cancer	1.13e-05	5.37e-05	CcSEcCtD
Lisinopril—Confusional state—Epirubicin—hematologic cancer	1.13e-05	5.35e-05	CcSEcCtD
Lisinopril—Diarrhoea—Betamethasone—hematologic cancer	1.12e-05	5.33e-05	CcSEcCtD
Lisinopril—Diarrhoea—Dexamethasone—hematologic cancer	1.12e-05	5.33e-05	CcSEcCtD
Lisinopril—Palpitations—Doxorubicin—hematologic cancer	1.12e-05	5.32e-05	CcSEcCtD
Lisinopril—Oedema—Epirubicin—hematologic cancer	1.12e-05	5.31e-05	CcSEcCtD
Lisinopril—Anaphylactic shock—Epirubicin—hematologic cancer	1.12e-05	5.31e-05	CcSEcCtD
Lisinopril—Hypotension—Methotrexate—hematologic cancer	1.11e-05	5.3e-05	CcSEcCtD
Lisinopril—Loss of consciousness—Doxorubicin—hematologic cancer	1.11e-05	5.29e-05	CcSEcCtD
Lisinopril—Infection—Epirubicin—hematologic cancer	1.11e-05	5.28e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—MTAP—hematologic cancer	1.11e-05	0.00017	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—hematologic cancer	1.11e-05	0.000169	CbGpPWpGaD
Lisinopril—Cough—Doxorubicin—hematologic cancer	1.1e-05	5.25e-05	CcSEcCtD
Lisinopril—Shock—Epirubicin—hematologic cancer	1.1e-05	5.22e-05	CcSEcCtD
Lisinopril—Thrombocytopenia—Epirubicin—hematologic cancer	1.09e-05	5.2e-05	CcSEcCtD
Lisinopril—Tachycardia—Epirubicin—hematologic cancer	1.09e-05	5.18e-05	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.09e-05	5.17e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—hematologic cancer	1.09e-05	0.000166	CbGpPWpGaD
Lisinopril—Skin disorder—Epirubicin—hematologic cancer	1.08e-05	5.16e-05	CcSEcCtD
Lisinopril—Dizziness—Betamethasone—hematologic cancer	1.08e-05	5.16e-05	CcSEcCtD
Lisinopril—Dizziness—Dexamethasone—hematologic cancer	1.08e-05	5.16e-05	CcSEcCtD
Lisinopril—Hyperhidrosis—Epirubicin—hematologic cancer	1.08e-05	5.13e-05	CcSEcCtD
Lisinopril—Insomnia—Methotrexate—hematologic cancer	1.08e-05	5.13e-05	CcSEcCtD
Lisinopril—Arthralgia—Doxorubicin—hematologic cancer	1.08e-05	5.13e-05	CcSEcCtD
Lisinopril—Myalgia—Doxorubicin—hematologic cancer	1.08e-05	5.13e-05	CcSEcCtD
Lisinopril—Chest pain—Doxorubicin—hematologic cancer	1.08e-05	5.13e-05	CcSEcCtD
Lisinopril—Anxiety—Doxorubicin—hematologic cancer	1.07e-05	5.11e-05	CcSEcCtD
Lisinopril—Nausea—Triamcinolone—hematologic cancer	1.07e-05	5.1e-05	CcSEcCtD
Lisinopril—Paraesthesia—Methotrexate—hematologic cancer	1.07e-05	5.1e-05	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.07e-05	5.09e-05	CcSEcCtD
Lisinopril—Discomfort—Doxorubicin—hematologic cancer	1.06e-05	5.06e-05	CcSEcCtD
Lisinopril—Anorexia—Epirubicin—hematologic cancer	1.06e-05	5.06e-05	CcSEcCtD
Lisinopril—Dyspnoea—Methotrexate—hematologic cancer	1.06e-05	5.06e-05	CcSEcCtD
Lisinopril—Somnolence—Methotrexate—hematologic cancer	1.06e-05	5.04e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—hematologic cancer	1.06e-05	0.000162	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—hematologic cancer	1.05e-05	0.000161	CbGpPWpGaD
Lisinopril—Dry mouth—Doxorubicin—hematologic cancer	1.05e-05	5.01e-05	CcSEcCtD
Lisinopril—Hypersensitivity—Prednisone—hematologic cancer	1.05e-05	5e-05	CcSEcCtD
Lisinopril—Dyspepsia—Methotrexate—hematologic cancer	1.05e-05	5e-05	CcSEcCtD
Lisinopril—Hypotension—Epirubicin—hematologic cancer	1.04e-05	4.96e-05	CcSEcCtD
Lisinopril—Vomiting—Betamethasone—hematologic cancer	1.04e-05	4.96e-05	CcSEcCtD
Lisinopril—Vomiting—Dexamethasone—hematologic cancer	1.04e-05	4.96e-05	CcSEcCtD
Lisinopril—Confusional state—Doxorubicin—hematologic cancer	1.04e-05	4.95e-05	CcSEcCtD
Lisinopril—Decreased appetite—Methotrexate—hematologic cancer	1.04e-05	4.93e-05	CcSEcCtD
Lisinopril—Rash—Dexamethasone—hematologic cancer	1.03e-05	4.92e-05	CcSEcCtD
Lisinopril—Rash—Betamethasone—hematologic cancer	1.03e-05	4.92e-05	CcSEcCtD
Lisinopril—Anaphylactic shock—Doxorubicin—hematologic cancer	1.03e-05	4.91e-05	CcSEcCtD
Lisinopril—Oedema—Doxorubicin—hematologic cancer	1.03e-05	4.91e-05	CcSEcCtD
Lisinopril—Dermatitis—Dexamethasone—hematologic cancer	1.03e-05	4.91e-05	CcSEcCtD
Lisinopril—Dermatitis—Betamethasone—hematologic cancer	1.03e-05	4.91e-05	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.03e-05	4.9e-05	CcSEcCtD
Lisinopril—Fatigue—Methotrexate—hematologic cancer	1.03e-05	4.89e-05	CcSEcCtD
Lisinopril—Headache—Betamethasone—hematologic cancer	1.03e-05	4.88e-05	CcSEcCtD
Lisinopril—Headache—Dexamethasone—hematologic cancer	1.03e-05	4.88e-05	CcSEcCtD
Lisinopril—Infection—Doxorubicin—hematologic cancer	1.03e-05	4.88e-05	CcSEcCtD
Lisinopril—Asthenia—Prednisone—hematologic cancer	1.02e-05	4.87e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hematologic cancer	1.02e-05	0.000156	CbGpPWpGaD
Lisinopril—Pain—Methotrexate—hematologic cancer	1.02e-05	4.85e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hematologic cancer	1.02e-05	0.000156	CbGpPWpGaD
Lisinopril—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.02e-05	4.84e-05	CcSEcCtD
Lisinopril—ABCB1—Transmembrane transport of small molecules—CYCS—hematologic cancer	1.02e-05	0.000156	CbGpPWpGaD
Lisinopril—Shock—Doxorubicin—hematologic cancer	1.02e-05	4.83e-05	CcSEcCtD
Lisinopril—Thrombocytopenia—Doxorubicin—hematologic cancer	1.01e-05	4.81e-05	CcSEcCtD
Lisinopril—Pruritus—Prednisone—hematologic cancer	1.01e-05	4.8e-05	CcSEcCtD
Lisinopril—Insomnia—Epirubicin—hematologic cancer	1.01e-05	4.8e-05	CcSEcCtD
Lisinopril—Tachycardia—Doxorubicin—hematologic cancer	1.01e-05	4.8e-05	CcSEcCtD
Lisinopril—Skin disorder—Doxorubicin—hematologic cancer	1e-05	4.77e-05	CcSEcCtD
Lisinopril—Paraesthesia—Epirubicin—hematologic cancer	1e-05	4.77e-05	CcSEcCtD
Lisinopril—Hyperhidrosis—Doxorubicin—hematologic cancer	9.98e-06	4.75e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—hematologic cancer	9.98e-06	0.000153	CbGpPWpGaD
Lisinopril—Dyspnoea—Epirubicin—hematologic cancer	9.95e-06	4.73e-05	CcSEcCtD
Lisinopril—Somnolence—Epirubicin—hematologic cancer	9.92e-06	4.72e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—FHL2—hematologic cancer	9.88e-06	0.000151	CbGpPWpGaD
Lisinopril—Anorexia—Doxorubicin—hematologic cancer	9.84e-06	4.68e-05	CcSEcCtD
Lisinopril—Feeling abnormal—Methotrexate—hematologic cancer	9.83e-06	4.68e-05	CcSEcCtD
Lisinopril—Dyspepsia—Epirubicin—hematologic cancer	9.82e-06	4.67e-05	CcSEcCtD
Lisinopril—Diarrhoea—Prednisone—hematologic cancer	9.76e-06	4.65e-05	CcSEcCtD
Lisinopril—Gastrointestinal pain—Methotrexate—hematologic cancer	9.75e-06	4.64e-05	CcSEcCtD
Lisinopril—Nausea—Betamethasone—hematologic cancer	9.73e-06	4.63e-05	CcSEcCtD
Lisinopril—Nausea—Dexamethasone—hematologic cancer	9.73e-06	4.63e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	9.73e-06	0.000149	CbGpPWpGaD
Lisinopril—Decreased appetite—Epirubicin—hematologic cancer	9.7e-06	4.62e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—AGRN—hematologic cancer	9.69e-06	0.000148	CbGpPWpGaD
Lisinopril—Hypotension—Doxorubicin—hematologic cancer	9.65e-06	4.59e-05	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.64e-06	4.58e-05	CcSEcCtD
Lisinopril—Fatigue—Epirubicin—hematologic cancer	9.62e-06	4.58e-05	CcSEcCtD
Lisinopril—Pain—Epirubicin—hematologic cancer	9.54e-06	4.54e-05	CcSEcCtD
Lisinopril—Constipation—Epirubicin—hematologic cancer	9.54e-06	4.54e-05	CcSEcCtD
Lisinopril—Urticaria—Methotrexate—hematologic cancer	9.47e-06	4.51e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	9.46e-06	0.000145	CbGpPWpGaD
Lisinopril—Dizziness—Prednisone—hematologic cancer	9.44e-06	4.49e-05	CcSEcCtD
Lisinopril—Abdominal pain—Methotrexate—hematologic cancer	9.43e-06	4.49e-05	CcSEcCtD
Lisinopril—Body temperature increased—Methotrexate—hematologic cancer	9.43e-06	4.49e-05	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	9.41e-06	4.48e-05	CcSEcCtD
Lisinopril—Insomnia—Doxorubicin—hematologic cancer	9.34e-06	4.44e-05	CcSEcCtD
Lisinopril—Paraesthesia—Doxorubicin—hematologic cancer	9.27e-06	4.41e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	9.21e-06	0.000141	CbGpPWpGaD
Lisinopril—Dyspnoea—Doxorubicin—hematologic cancer	9.21e-06	4.38e-05	CcSEcCtD
Lisinopril—Feeling abnormal—Epirubicin—hematologic cancer	9.2e-06	4.38e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—IDH2—hematologic cancer	9.19e-06	0.000141	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—HMMR—hematologic cancer	9.19e-06	0.000141	CbGpPWpGaD
Lisinopril—Somnolence—Doxorubicin—hematologic cancer	9.18e-06	4.37e-05	CcSEcCtD
Lisinopril—Gastrointestinal pain—Epirubicin—hematologic cancer	9.13e-06	4.34e-05	CcSEcCtD
Lisinopril—Dyspepsia—Doxorubicin—hematologic cancer	9.09e-06	4.33e-05	CcSEcCtD
Lisinopril—Vomiting—Prednisone—hematologic cancer	9.07e-06	4.32e-05	CcSEcCtD
Lisinopril—Rash—Prednisone—hematologic cancer	9e-06	4.28e-05	CcSEcCtD
Lisinopril—Dermatitis—Prednisone—hematologic cancer	8.99e-06	4.28e-05	CcSEcCtD
Lisinopril—Decreased appetite—Doxorubicin—hematologic cancer	8.98e-06	4.27e-05	CcSEcCtD
Lisinopril—Headache—Prednisone—hematologic cancer	8.94e-06	4.25e-05	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Doxorubicin—hematologic cancer	8.92e-06	4.24e-05	CcSEcCtD
Lisinopril—Fatigue—Doxorubicin—hematologic cancer	8.9e-06	4.24e-05	CcSEcCtD
Lisinopril—Urticaria—Epirubicin—hematologic cancer	8.87e-06	4.22e-05	CcSEcCtD
Lisinopril—Pain—Doxorubicin—hematologic cancer	8.83e-06	4.2e-05	CcSEcCtD
Lisinopril—Constipation—Doxorubicin—hematologic cancer	8.83e-06	4.2e-05	CcSEcCtD
Lisinopril—Body temperature increased—Epirubicin—hematologic cancer	8.82e-06	4.2e-05	CcSEcCtD
Lisinopril—Abdominal pain—Epirubicin—hematologic cancer	8.82e-06	4.2e-05	CcSEcCtD
Lisinopril—Hypersensitivity—Methotrexate—hematologic cancer	8.79e-06	4.18e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	8.71e-06	0.000133	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ARNTL—hematologic cancer	8.64e-06	0.000132	CbGpPWpGaD
Lisinopril—Asthenia—Methotrexate—hematologic cancer	8.56e-06	4.07e-05	CcSEcCtD
Lisinopril—Feeling abnormal—Doxorubicin—hematologic cancer	8.51e-06	4.05e-05	CcSEcCtD
Lisinopril—Nausea—Prednisone—hematologic cancer	8.48e-06	4.03e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	8.48e-06	0.00013	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	8.45e-06	0.000129	CbGpPWpGaD
Lisinopril—Gastrointestinal pain—Doxorubicin—hematologic cancer	8.44e-06	4.02e-05	CcSEcCtD
Lisinopril—Pruritus—Methotrexate—hematologic cancer	8.44e-06	4.01e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—CA9—hematologic cancer	8.4e-06	0.000129	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ACP5—hematologic cancer	8.4e-06	0.000129	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—NCOR2—hematologic cancer	8.29e-06	0.000127	CbGpPWpGaD
Lisinopril—Hypersensitivity—Epirubicin—hematologic cancer	8.22e-06	3.91e-05	CcSEcCtD
Lisinopril—Urticaria—Doxorubicin—hematologic cancer	8.2e-06	3.9e-05	CcSEcCtD
Lisinopril—Body temperature increased—Doxorubicin—hematologic cancer	8.16e-06	3.88e-05	CcSEcCtD
Lisinopril—Abdominal pain—Doxorubicin—hematologic cancer	8.16e-06	3.88e-05	CcSEcCtD
Lisinopril—Diarrhoea—Methotrexate—hematologic cancer	8.16e-06	3.88e-05	CcSEcCtD
Lisinopril—Asthenia—Epirubicin—hematologic cancer	8.01e-06	3.81e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—IDH1—hematologic cancer	7.9e-06	0.000121	CbGpPWpGaD
Lisinopril—Pruritus—Epirubicin—hematologic cancer	7.9e-06	3.76e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	7.89e-06	0.000121	CbGpPWpGaD
Lisinopril—Dizziness—Methotrexate—hematologic cancer	7.89e-06	3.75e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	7.83e-06	0.00012	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GSTO1—hematologic cancer	7.81e-06	0.00012	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—TXN—hematologic cancer	7.81e-06	0.00012	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ABCC3—hematologic cancer	7.81e-06	0.00012	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—SPHK1—hematologic cancer	7.64e-06	0.000117	CbGpPWpGaD
Lisinopril—Diarrhoea—Epirubicin—hematologic cancer	7.64e-06	3.63e-05	CcSEcCtD
Lisinopril—Hypersensitivity—Doxorubicin—hematologic cancer	7.61e-06	3.62e-05	CcSEcCtD
Lisinopril—Vomiting—Methotrexate—hematologic cancer	7.58e-06	3.61e-05	CcSEcCtD
Lisinopril—Rash—Methotrexate—hematologic cancer	7.52e-06	3.58e-05	CcSEcCtD
Lisinopril—Dermatitis—Methotrexate—hematologic cancer	7.51e-06	3.57e-05	CcSEcCtD
Lisinopril—Headache—Methotrexate—hematologic cancer	7.47e-06	3.55e-05	CcSEcCtD
Lisinopril—Asthenia—Doxorubicin—hematologic cancer	7.41e-06	3.53e-05	CcSEcCtD
Lisinopril—Dizziness—Epirubicin—hematologic cancer	7.38e-06	3.51e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—UGT1A1—hematologic cancer	7.34e-06	0.000112	CbGpPWpGaD
Lisinopril—Pruritus—Doxorubicin—hematologic cancer	7.31e-06	3.48e-05	CcSEcCtD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	7.19e-06	0.00011	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CRABP1—hematologic cancer	7.14e-06	0.000109	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—SLC22A1—hematologic cancer	7.14e-06	0.000109	CbGpPWpGaD
Lisinopril—Vomiting—Epirubicin—hematologic cancer	7.1e-06	3.38e-05	CcSEcCtD
Lisinopril—Nausea—Methotrexate—hematologic cancer	7.08e-06	3.37e-05	CcSEcCtD
Lisinopril—Diarrhoea—Doxorubicin—hematologic cancer	7.07e-06	3.36e-05	CcSEcCtD
Lisinopril—Rash—Epirubicin—hematologic cancer	7.04e-06	3.35e-05	CcSEcCtD
Lisinopril—Dermatitis—Epirubicin—hematologic cancer	7.03e-06	3.35e-05	CcSEcCtD
Lisinopril—Headache—Epirubicin—hematologic cancer	6.99e-06	3.33e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—ALOX5—hematologic cancer	6.96e-06	0.000107	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	6.96e-06	0.000107	CbGpPWpGaD
Lisinopril—Dizziness—Doxorubicin—hematologic cancer	6.83e-06	3.25e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—NUP98—hematologic cancer	6.74e-06	0.000103	CbGpPWpGaD
Lisinopril—Nausea—Epirubicin—hematologic cancer	6.63e-06	3.15e-05	CcSEcCtD
Lisinopril—Vomiting—Doxorubicin—hematologic cancer	6.57e-06	3.12e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—ADCY7—hematologic cancer	6.55e-06	0.0001	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—NCOA3—hematologic cancer	6.55e-06	0.0001	CbGpPWpGaD
Lisinopril—Rash—Doxorubicin—hematologic cancer	6.51e-06	3.1e-05	CcSEcCtD
Lisinopril—Dermatitis—Doxorubicin—hematologic cancer	6.51e-06	3.1e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—NUP214—hematologic cancer	6.5e-06	9.94e-05	CbGpPWpGaD
Lisinopril—Headache—Doxorubicin—hematologic cancer	6.47e-06	3.08e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—ABCG2—hematologic cancer	6.37e-06	9.74e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—MTR—hematologic cancer	6.37e-06	9.74e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ENO2—hematologic cancer	6.24e-06	9.55e-05	CbGpPWpGaD
Lisinopril—Nausea—Doxorubicin—hematologic cancer	6.13e-06	2.92e-05	CcSEcCtD
Lisinopril—ABCB1—Metabolism—GSTT1—hematologic cancer	6.06e-06	9.27e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—SDC1—hematologic cancer	5.92e-06	9.06e-05	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	5.88e-06	8.99e-05	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.67e-06	8.68e-05	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	5.31e-06	8.12e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—NQO1—hematologic cancer	5.03e-06	7.7e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CD44—hematologic cancer	5.03e-06	7.7e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CYCS—hematologic cancer	4.76e-06	7.29e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—HSP90AA1—hematologic cancer	4.73e-06	7.24e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GSTP1—hematologic cancer	4.2e-06	6.42e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GSTM1—hematologic cancer	3.86e-06	5.9e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—NCOR1—hematologic cancer	3.86e-06	5.9e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—MTHFR—hematologic cancer	3.41e-06	5.22e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.86e-06	4.38e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CREBBP—hematologic cancer	2.66e-06	4.06e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.52e-06	3.85e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ALB—hematologic cancer	2.49e-06	3.8e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PIK3R1—hematologic cancer	2.38e-06	3.64e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.19e-06	3.36e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PTEN—hematologic cancer	1.9e-06	2.9e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—EP300—hematologic cancer	1.81e-06	2.77e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.34e-06	2.05e-05	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—AKT1—hematologic cancer	1.09e-06	1.67e-05	CbGpPWpGaD
